Mesoporous polydopamine carrying sorafenib and SPIO nanoparticles for MRI-guided ferroptosis cancer therapy

Iron-based nanomaterials as the main ferroptosis-inducing platforms are more promising because iron itself is a key component in the Fenton reaction to produce ROS. However, the Fe dose needs to be very high in order to induce ferroptosis-based cancer treatment using the SPIO NPs. Therefore, it is s...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2020-04, Vol.320, p.392-403
Main Authors: Guan, Qingqing, Guo, Ruomi, Huang, Shihui, Zhang, Fan, Liu, Jie, Wang, Zhiyong, Yang, Xi, Shuai, Xintao, Cao, Zhong
Format: Article
Language:English
Subjects:
Cancer theranostics
Ferroptosis
Mesoporous polydopamine
Sorafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron-based nanomaterials as the main ferroptosis-inducing platforms are more promising because iron itself is a key component in the Fenton reaction to produce ROS. However, the Fe dose needs to be very high in order to induce ferroptosis-based cancer treatment using the SPIO NPs. Therefore, it is still of great challenge to enhance the efficacy of ferroptosis-based cancer therapy by associating the iron-based nanomaterials with other components and therapeutic modalities. In this study, sorafenib (SRF) and ultrasmall SPIO nanoparticles were loaded into the mesopores and onto the surface of MPDA NPs to form SRF@MPDA-SPIO nanoparticles. SPIO loading endowed the system with iron-supply for ferroptosis and made the system MRI-visible. Meanwhile, SRF was able to induce ferroptosis in cancer cells with lower Fe dose. Furthermore, the heat generated by MPDA NPs upon laser irradiation offered a moderate PTT to boost the ferroptosis effect. The SRF@MPDA-SPIO exhibited biocompatibility highly desirable for in vivo application and superior anticancer therapy via the combination of ferroptosis and photothermal therapy. Multiple responsive (pH, temperature and GSH) drug delivery nanoplatform (SRF@MPDA-SPIO) have been developed for MR imaging-guided ferroptosis-photothermal combined therapy. [Display omitted] •Sorafenib and SPIO were loaded to the mesopores and surface of MPDA NPs to form SRF@MPDA-SPIO nanoparticles.•The nanodrug was responsive to pH, temperature and glutathane to release ferric/ferrous ions and Sorafenib.•The nanodrug represents a theranostic system allowing MRI to guide a combination ferroptosis and photothermal therapy.
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2020.01.048